Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Perspectives on factor Xa inhibition.

R Rai1, P A Sprengeler, K C Elrod

  • 1Axys Pharmaceuticals, Inc, 180 Kimball Way, South San Francisco, CA 94080, USA. roopa_rai@axyspharm.com

Current Medicinal Chemistry
|February 15, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early Intervention in Post-operative Infectious Spondylodiscitis: Outcome of Aggressive Transforaminal Lumbar Interbody Fusion.

Malaysian orthopaedic journal·2024
Same author

HLA-E and NKG2A Mediate Resistance to BCG Immunotherapy in Non-Muscle-Invasive Bladder Cancer.

bioRxiv : the preprint server for biology·2024
Same author

MEDITERRANEAN DIET AND ITS IMPACT ON THE ILLNESS CHARACTERISTIC OF YOUTH WITH IRRITABLE BOWEL CONDITION.

Georgian medical news·2024
Same author

Dynamic Contrast-enhanced Magnetic Resonance Imaging Evaluation of Whole Tumour Perfusion Heterogeneity Predicts Distant Disease-free Survival in Locally Advanced Rectal Cancer.

Clinical oncology (Royal College of Radiologists (Great Britain))·2022
Same author

Comment on: Multimodal analgesia with thoracic epidural after transthoracic oesophagectomy: Do we need more evidence?

The British journal of surgery·2021
Same author

Quantitative MRI: Defining repeatability, reproducibility and accuracy for prostate cancer imaging biomarker development.

Magnetic resonance imaging·2021
Same journal

Knockdown of circFGFR2 inhibits prostate cancer cell metastasis and proliferation by targeting miR-221-5p/ SMUG1 pathway.....

Current medicinal chemistry·2026
Same journal

LncRNA signature associated with amino acid metabolism: A novel prognostic tool for Clear Cell Renal Cell Carcinoma.

Current medicinal chemistry·2026
Same journal

HRI Kinase Modulation by BTdCPU as a Therapeutic Strategy for Bortezomib Resistance in Prostate Cancer.

Current medicinal chemistry·2026
Same journal

EGFR Dysregulation in Cancer: From Molecular Mechanisms and Key Mutations to Evolving TKI Strategies and Resistance Mitigation.

Current medicinal chemistry·2026
Same journal

DHRS2 as a Novel Thalidomide Target Regulating Mitophagy and Inflammation in Head and Neck Squamous Cell Carcinoma.

Current medicinal chemistry·2026
Same journal

Synthetic AtMP2 from Anabas testudineus: Comprehensive ADMET and In Vivo Toxicity Assessment to Enable Future Therapeutic Development.

Current medicinal chemistry·2026
See all related articles

Factor Xa inhibitors are promising for treating thrombosis by blocking blood clot formation. Developing selective inhibitors is key to preventing side effects from targeting this crucial enzyme in coagulation.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Medicinal Chemistry

Background:

  • Blood coagulation is a complex enzymatic cascade essential for hemostasis, culminating in fibrin clot formation.
  • Factor Xa is a critical enzyme in the common pathway of coagulation, making it a key target for anticoagulant therapies.
  • Thrombosis treatment necessitates potent and selective inhibition of Factor Xa to minimize off-target effects.

Purpose of the Study:

  • To review strategies for developing oral anticoagulants targeting Factor Xa.
  • To explore structural features of protein-ligand binding for achieving Factor Xa potency and selectivity.
  • To discuss lead molecules and their binding motifs for effective Factor Xa inhibition.

Main Methods:

  • Review of current literature on Factor Xa inhibitor development.

Related Experiment Videos

  • Analysis of structural data on protein-ligand interactions within the Factor Xa active site.
  • Discussion of selected drug candidates and their binding characteristics.

    • Main Results:

    • Factor Xa is a validated target for oral anticoagulants, with inhibitors showing promise in preclinical models.
    • Achieving selectivity for Factor Xa over other serine proteases is challenging due to conserved active site structures.
    • Specific binding motifs and structural features are being exploited to design potent and selective Factor Xa inhibitors.

    Conclusions:

    • Factor Xa inhibitors represent a significant advancement in anticoagulant therapy.
    • Structural insights into protein-ligand interactions are crucial for developing selective and potent Factor Xa inhibitors.
    • Continued research into lead molecules and binding strategies will advance oral anticoagulant drug discovery.